Fate Therapeutics Stock Analysis


USD 20.40  0.51  2.44%   

The latest Fate Therapeutics price dip could raise concerns from shareholders as the firm is trading at a share price of 20.40 on 1,112,611 in volume. The company management teams were unable to exploit market volatilities in November. However, diversifying your overall positions with Fate Therapeutics can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.32. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Fate Therapeutics partners.
Please check Investing Opportunities.
The Fate Therapeutics stock analysis report makes it easy to digest most publicly released information about Fate Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Fate Therapeutics Stock analysis module also helps to analyze the Fate Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Fate Therapeutics Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The book value of Fate Therapeutics was currently reported as 5.33. The company recorded a loss per share of 2.44. Fate Therapeutics had not issued any dividends in recent years. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people. To learn more about Fate Therapeutics call Scott Wolchko at 858 875 1800 or check out https://www.fatetherapeutics.com.

Fate Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fate Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fate Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Fate Therapeutics generated a negative expected return over the last 90 days
Fate Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 55.85 M. Net Loss for the year was (212.15 M) with profit before overhead, payroll, taxes, and interest of 55.85 M.
Fate Therapeutics currently holds about 568.85 M in cash with (162.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86.
Fate Therapeutics has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors - Marketscreener.com

Fate Therapeutics Upcoming and Recent Events

Earnings reports are used by Fate Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fate Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Fate Therapeutics Largest EPS Surprises

Earnings surprises can significantly impact Fate Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Fate Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Fate Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Fate Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Fate Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
30th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
13th of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
28th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
10th of February 2022
Unclassified Corporate Event
9th of February 2022
Unclassified Corporate Event

Fate Therapeutics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Fate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fate Therapeutics backward and forwards among themselves. Fate Therapeutics' institutional investor refers to the entity that pools money to purchase Fate Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares10 K224 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares10 K247 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares10 K387 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares13.4 K782 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares8.2 K487 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares8.2 K715 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares8.2 K677 K
Note, although Fate Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Fate Therapeutics Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.03 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fate Therapeutics's market, we take the total number of its shares issued and multiply it by Fate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Fate Therapeutics Profitablity

Fate Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Fate Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Fate Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Fate Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Fate Therapeutics' profitability requires more research than a typical breakdown of Fate Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(40.82) (44.04) 
Return on Average Assets(27.48) (29.65) 
Return on Average Equity(39.90) (43.06) 
Return on Invested Capital(0.24) (0.25) 
Return on Sales(3.80) (4.10) 

Management Efficiency

The entity has return on total asset (ROA) of (0.2259) % which means that it has lost $0.2259 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.471) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics management efficiency ratios could be used to measure how well fate therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 5, 2022, Return on Investment is expected to decline to -44.04. In addition to that, Return on Average Assets is expected to decline to -29.65. Fate Therapeutics Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 633.41 Million. The current year Assets Non Current is expected to grow to about 310.8 M, whereas Return on Average Assets are forecasted to decline to (29.65) .
Last ReportedProjected for 2022
Book Value per Share 7.17  7.73 
Enterprise Value over EBIT(26.00) (26.68) 
Enterprise Value over EBITDA(26.91) (27.62) 
Price to Book Value 8.23  7.76 
Tangible Assets Book Value per Share 9.72  10.49 
Enterprise Value5.6 BB
Tangible Asset Value921.5 M994.2 M

Technical Drivers

As of the 5th of December, Fate Therapeutics shows the coefficient of variation of (1,778), and Mean Deviation of 3.36. Fate Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Fate Therapeutics, which can be compared to its rivals. Please confirm Fate Therapeutics variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Fate Therapeutics is priced favorably, providing market reflects its regular price of 20.4 per share. Given that Fate Therapeutics has jensen alpha of (0.47), we urge you to verify Fate Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Fate Therapeutics Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Fate Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Fate Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Fate Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Fate Therapeutics Predictive Daily Indicators

Fate Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fate Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Fate Therapeutics Forecast Models

Fate Therapeutics time-series forecasting models is one of many Fate Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fate Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Fate Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Fate Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fate Therapeutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Fate Therapeutics. By using and applying Fate Therapeutics Stock analysis, traders can create a robust methodology for identifying Fate Therapeutics entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 0.90  0.89 

Current Fate Therapeutics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fate Therapeutics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fate Therapeutics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Fate Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Fate Therapeutics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Fate Therapeutics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Fate Therapeutics, talking to its executives and customers, or listening to Fate Therapeutics conference calls.
Fate Therapeutics Analyst Advice Details

Fate Therapeutics Stock Analysis Indicators

Fate Therapeutics stock analysis indicators help investors evaluate how Fate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Fate Therapeutics shares will generate the highest return on investment. By understating and applying Fate Therapeutics stock analysis, traders can identify Fate Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow182574000.00
Common Stock Shares Outstanding82385319.00
Total Stockholder Equity678838000.00
DescriptionFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia B-cell lymphoma, and advanced solid tum
Total Cashflows From Investing Activities-324023000.00
Property Plant And Equipment Net162249000.00
Retained Earnings-769083000.00
Cash And Short Term Investments615910000.00
Retained Earnings Total Equity-769083000.00
Accounts Payable8612000.00
Net Debt-18765000.00
50 Day M A20.8718
Total Current Liabilities81284000.00
Currency CodeUSD
Other Operating Expenses272840000.00
Non Current Assets Total288043000.00
Common Stock Total Equity96000.00
Non Currrent Assets Other25130000.00
Please check Investing Opportunities. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for analysis

When running Fate Therapeutics price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Transaction History
View history of all your transactions and understand their impact on performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Fate Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.